BPI France et al. in €18.5m series-B round for HalioDX

The series-B round saw BPI France, Capricorn and Amundi back the company for the first time.

BPI France used its Programme de Soutien à l'Innovation Majeure (PSIM) fund for the transaction, which held a close on €150m.

Capricorn and Amundi used the Quest for Growth vehicle for the transaction. It is a public alternative investment fund with fixed capital.

Historical investors MI Care, Sham, Turenne Capital, BNP Paribas Développement and Sofipaca also took part in the round. Sham and Turenne used their Sham Innovation Santé fund, launched in 2014.

The company intends to use the funds to accelerate product development and set up commercial activities in the US.

Company
HalioDX, founded in 2015 and headquartered in Marseille, is a diagnostics company. It develops Immunoscore, a diagnostic platform based on the analysis of the tumour microenvironment combining immunohistochemistry and advanced digital pathology. HalioDX has also developed an immune biomarker partnering programme. The company employs 130 staff.

People
HalioDX – Vincent Fert (CEO).
BPI France – Olivier Martinez (senior investment director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• BPI France
• Venture
• BNP Paribas Développement